Japanese Drug Maker To Seek New Trial For Parkinson’s Drug Approval
This article was originally published in PharmAsia News
Japan's Kyowa Hakko Kirin says it plans to put its Parkinson's disease drug through Phase III clinical trials later this year. The drug, KW-6002 (istradefylline), targets the brain's adenosine A2A receptor to prevent destruction of dopamine. The drug is to be used in conjunction with current treatments. The company failed in a bid to get U.S. approval last year when the FDA said it needed more data. Now that Phase II trials in Japan have been conducted, the company feels it is time to make a new approval attempt and is considering a license to another drug maker. (Click here for more - a subscription may be required
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.